We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

54 hedge funds and large institutions have $103M invested in Concert Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

25% more capital invested

Capital invested by funds: $82.6M → $103M (+$20.9M)

6% more funds holding

Funds holding: 51 → 54 (+3)

8% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
54
Holders Change
+3
Holders Change %
+5.88%
% of All Funds
1.44%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
17
Increased
14
Reduced
13
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Senzar Asset Management
New York
+$7.81M
2
ISL
Ingalls & Snyder LLC
New York
+$4.53M
3
QF
QVT Financial
New York
+$3.36M
4
Millennium Management
Millennium Management
New York
+$3.13M
5
BFA
BlackRock Fund Advisors
California
+$2.76M

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$3.82M
2
GTC
Ghost Tree Capital
New York
-$3.54M
3
RFC
Russell Frank Company
Washington
-$1.44M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.29M
5
TI
Turner Investments
Pennsylvania
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$16.1M – – –
SAM
2
Senzar Asset Management
New York
$11.5M +$7.81M +605,000 +232%
Franklin Resources
3
Franklin Resources
California
$9.15M – – –
BBA
4
Baker Bros. Advisors
New York
$6.73M +$696K +53,922 +12%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$6.66M -$442K -34,200 -6%
ISL
6
Ingalls & Snyder LLC
New York
$4.67M +$4.53M +351,000 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$4.67M -$728K -56,349 -14%
WSA
8
Wall Street Associates
California
$3.91M – – –
UBS Group
9
UBS Group
Switzerland
$3.62M +$3.51M +272,020 New
QF
10
QVT Financial
New York
$3.38M +$3.36M +259,999 New
Millennium Management
11
Millennium Management
New York
$3.23M +$3.13M +242,080 New
BA
12
BlackRock Advisors
Delaware
$3.21M +$444K +34,385 +17%
BFA
13
BlackRock Fund Advisors
California
$3.1M +$2.76M +214,118 +1,140%
Principal Financial Group
14
Principal Financial Group
Iowa
$2.33M -$45.2K -3,500 -2%
PI
15
Putnam Investments
Massachusetts
$2.17M – – –
SFM
16
Sphera Funds Management
Israel
$2M +$1.64M +127,300 +561%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$1.79M -$494K -38,236 -22%
TC
18
TFS Capital
Pennsylvania
$1.66M +$1.3M +100,404 +417%
BIM
19
Bogle Investment Management
Massachusetts
$1.52M +$1.47M +113,894 New
SIM
20
Spark Investment Management
New York
$1.47M +$564K +43,700 +65%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$1.18M – – –
TI
22
Turner Investments
Pennsylvania
$1.07M -$1.23M -95,175 -54%
GPCM
23
Granite Point Capital Management
Massachusetts
$936K +$907K +70,264 New
BIT
24
BlackRock Institutional Trust
California
$842K +$38K +2,941 +5%
Citadel Advisors
25
Citadel Advisors
Florida
$791K +$767K +59,417 New
1
2 3

CNCE Hedge Fund Activity: Q4 2014 in Review

54 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q4 2014, worth a combined $103M — up 25% from $82.6M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CNCE positions and 13 closed out — a net gain of 4 holders — while 14 added to existing stakes and 13 trimmed.

The largest buyer was Senzar Asset Management, adding an estimated $7.81M. The largest seller was EAM Investors, exiting entirely with an estimated $3.82M sold.

  • 54 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q4 2014, up from 51 in Q3 2014.
  • Funds reported $103M of Concert Pharmaceuticals, Inc. stock for Q4 2014, up 25% quarter-over-quarter.
  • 17 funds opened new Concert Pharmaceuticals, Inc. positions in Q4 2014 and 13 closed out, a net change of +4 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q4 2014 was Senzar Asset Management, an estimated $7.81M added.
  • The largest Concert Pharmaceuticals, Inc. seller in Q4 2014 was EAM Investors, an estimated $3.82M sold.

Based on aggregated 13F filings for Q4 2014.